Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) Director Michael Hayden bought 5,000 shares of the stock in a transaction on Tuesday, November 10th. The shares were bought at an average price of $29.64 per share, for a total transaction of $148,200.00. Following the acquisition, the director owned 27,000 shares in the company, valued at $800,280. The trade was a 22.73% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Ionis Pharmaceuticals Stock Performance
NASDAQ IONS opened at $29.06 on Monday. The company has a quick ratio of 5.36, a current ratio of 5.43 and a debt-to-equity ratio of 3.42. The stock has a market cap of $4.84 billion, a price-to-earnings ratio of -8.75 and a beta of 0.43. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $27.25 and a fifty-two week high of $86.74. The business has a fifty day moving average of $43.65 and a 200-day moving average of $64.57.
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.57. Ionis Pharmaceuticals had a negative return on equity of 120.62% and a negative net margin of 56.98%. The firm had revenue of $242.72 million during the quarter, compared to analysts’ expectations of $178.17 million. During the same quarter last year, the business posted ($0.80) EPS. The firm’s quarterly revenue was up 54.8% compared to the same quarter last year. As a group, analysts predict that Ionis Pharmaceuticals, Inc. will post -3.57 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Ionis Pharmaceuticals
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Alyeska Investment Group L.P. grew its stake in shares of Ionis Pharmaceuticals by 199.7% in the second quarter. Alyeska Investment Group L.P. now owns 1,417,916 shares of the company’s stock valued at $112,427,000 after buying an additional 944,766 shares in the last quarter. Pictet Asset Management Holding SA grew its position in Ionis Pharmaceuticals by 21.7% in the third quarter. Pictet Asset Management Holding SA now owns 1,944,020 shares of the company’s stock valued at $87,249,000 after acquiring an additional 347,022 shares in the last quarter. Bank of America Corp DE acquired a new position in shares of Ionis Pharmaceuticals during the second quarter worth $62,718,000. Groupama Asset Managment boosted its stake in shares of Ionis Pharmaceuticals by 7.5% in the first quarter. Groupama Asset Managment now owns 824,540 shares of the company’s stock valued at $61,915,000 after purchasing an additional 57,651 shares during the period. Finally, GW&K Investment Management LLC grew its holdings in Ionis Pharmaceuticals by 79.6% during the 3rd quarter. GW&K Investment Management LLC now owns 1,341,315 shares of the company’s stock valued at $59,890,000 after purchasing an additional 594,349 shares in the last quarter. Institutional investors and hedge funds own 93.86% of the company’s stock.
Wall Street Analyst Weigh In
IONS has been the topic of several analyst reports. JPMorgan Chase & Co. decreased their price objective on Ionis Pharmaceuticals from $76.00 to $70.00 and set an “overweight” rating on the stock in a report on Tuesday, September 22nd. Royal Bank Of Canada lowered their price target on Ionis Pharmaceuticals from $85.00 to $60.00 and set an “outperform” rating for the company in a report on Tuesday, November 10th. Canaccord Genuity Group lowered their target price on shares of Ionis Pharmaceuticals from $95.00 to $85.00 and set a “buy” rating for the company in a report on Tuesday, September 8th. Bank of America reissued a “buy” rating and set a $63.00 price objective on shares of Ionis Pharmaceuticals in a research note on Tuesday, November 10th. Finally, Citigroup reiterated a “buy” rating on shares of Ionis Pharmaceuticals in a report on Wednesday, October 21st. Nineteen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Ionis Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $75.71.
Check Out Our Latest Research Report on IONS
More Ionis Pharmaceuticals News
Investors following IONS have been watching these news items:
- Positive Sentiment: Director Michael Hayden purchased 5,000 shares for $148,200, increasing his Ionis holdings by 22.7%—an insider buy that may signal confidence in the company. SEC filing
- Positive Sentiment: Two-year DAWNZERA data presented at the ACAAI meeting supported durable efficacy and disease control for hereditary angioedema, adding clinical evidence for the drug. Wells Fargo also rated Ionis a Buy. DAWNZERA long-term data Wells Fargo rating
- Negative Sentiment: Several firms—including Morgan Stanley, Needham, HC Wainwright, Oppenheimer and Goldman Sachs—cut price expectations; a separate analyst downgrade was associated with a sharp recent decline in the shares. Artisan Partners also said its small-cap growth strategy exited Ionis following sequential Phase 3 setbacks. Morgan Stanley price target Artisan Partners exit
About Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.
Recommended Stories
- Five stocks we like better than Ionis Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
